EAACI Congress 2023
BackAllergen immunotherapy 1
Friday 09 Jun, 12:00 PM -
13:00 PM CEST
Poster Zone C
Posters
12:00
Activation of the aryl hydrocarbon receptor improves outcome of allergen-specific immunotherapy: A novel adjuvant option?
12:00
Allergen immunotherapy in United Arab Emirates and Kingdom of Saudia Arabia: what are the unmet needs?
12:00
Allergenic activity of a mixture of depigmented-polymerized extracts from Platanus acerifolia and Olea europaea pollen
12:00
Allergoid implant for allergen immunotherapy: stability and long-term in-vitro release
12:00
Anaphylaxis caused by AIT due co-factors: a case report
12:00
BSP163: Establishment of replacement batches for the recombinant major allergens Bet v 1 and Phl p 5a Ph. Eur. reference standards
12:00
Cat and dog Specific immunotherapy impact on quality of life and self-reported satisfaction in a real-world setting
12:00
Clinical Development of Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergic patients
12:00
Construction of peptide-based virus‐like-particle vaccines for treating shrimp allergy
12:00
Cup a 1, precision immunotherapy, a first safety real life study
12:00
Current status of the therapy allergen ordinance in Germany – practical implications for product selection
12:00
DRAGO Application to Optimize Use of Allergen Immunotherapy: Trends & Acceptance
12:00
EAIT-CSU; Extensive Allergen Immunotherapy Protocol for Management of Chronic Spontaneous Urticaria
12:00
Effectiveness of allergen immunotherapy (AIT) under real life conditions from a German retrospective cohort study in children, adolescents and adults with house dust mite (HDM) induced allergic rhinitis (AR) and asthma (AA)
12:00
Evaluation of the cytokine response induced by specific allergen immunotherapy in patients with hymenoptera venom allergy
12:00
Mannan-conjugated birch pollen allergens continuously reduce the combined symptom and medication score with increasing treatment duration in birch pollen allergic patients
12:00
SQ SCIT, evidence based treatment for allergic respiratory disease
12:00
Safety and effectiveness of 300IR house dust mite sublingual tablet over 4 years of routine use: results of a post-marketing observational drug-use study
12:00
Safety and tolerability of allergen immunotherapy in patients with respiratory allergy
12:00
Stability, allergenicity, in vitro safety profile and immune response of a mixture of grass mix pollen- cat dander depigmented polymerized extracts
12:00
Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids – clinical data from 3 sequential trials
12:00
Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids – immunological data from 3 sequential trials
12:00
Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids – safety data from 3 sequential trials
